Source Paper
Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and α-synuclein
Francesco Fornai, Oliver M. Schlüter, Paola Lenzi, Marco Gesi, Riccardo Ruffoli et al.
Proceedings of the National Academy of Sciences • 2005
Continuous MPTP Infusion
Objective: To develop a mouse Parkinson's disease model using continuous MPTP administration via osmotic minipump to induce progressive behavioral changes, neurodegeneration, and Parkinson-like syndrome features including dopamine depletion, nigral cell loss, and inclusion body formation
This is a Continuous MPTP Infusion protocol using mouse as the model organism. The procedure involves 5 procedural steps, 2 materials. Extracted from a 2005 paper published in Proceedings of the National Academy of Sciences.
Model and subjects
mouse • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
MPTP Administration Setup • Behavioral Monitoring • Neurochemical Assessment
Primary readouts
- Progressive behavioral changes
- Striatal dopamine depletion
- Nigral cell loss
- Formation of nigral inclusions immunoreactive for ubiquitin and α-synuclein
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
MPTP Administration Setup
Implant osmotic minipump for continuous MPTP delivery to mice
Note: Continuous administration is critical to produce progressive behavioral changes and inclusion body formation, unlike sporadic injections
View evidence from paper
“continuous MPTP administration with an osmotic minipump and mimics many features of the human disease”
Behavioral Monitoring
Monitor progressive behavioral changes in mice receiving continuous MPTP infusion
Note: Only continuous MPTP administration produced progressive behavioral changes, not sporadic injections
View evidence from paper
“only continuous administration of MPTP produced progressive behavioral changes and triggered formation of nigral inclusions”
Neurochemical Assessment
Measure striatal dopamine depletion and metabolic activation via glucose uptake
Note: Both sporadic and continuous MPTP led to dopamine depletion, but only continuous caused long-lasting metabolic changes
View evidence from paper
“only continuous MPTP infusions caused long-lasting activation of glucose uptake and inhibition of the ubiquitin-proteasome system”
Neuropathological Analysis
Examine nigral tissue for inclusion bodies immunoreactive for ubiquitin and α-synuclein
Note: Inclusion body formation occurred only with continuous MPTP administration
View evidence from paper
“only continuous administration of MPTP produced progressive behavioral changes and triggered formation of nigral inclusions immunoreactive for ubiquitin and α-synuclein”
Comparative Analysis with α-synuclein Knockout Mice
Administer continuous MPTP to mice lacking α-synuclein and compare outcomes to wild-type mice
Note: α-synuclein knockout mice showed metabolic activation but alleviated behavioral symptoms and neuronal cell death
View evidence from paper
“In mice lacking α-synuclein, continuous MPTP delivery still induced metabolic activation, but induction of behavioral symptoms and neuronal cell death were almost completely alleviated”